ADZA Adeza Biomedical (MM)

Adeza (NASDAQ:ADZA) today announced that Nancy D. Burrus, general partner of Indosuez Ventures, resigned from the company's board of directors. Ms. Burrus was also a member of the board's compensation and audit committees. Adeza's board currently includes six directors, including five independent directors. "Nancy has been part of the Adeza team for more than 11 years and we are thankful for her dedication to the company," said Emory V. Anderson, president and chief executive officer. "Her advice and counsel have been a tremendous asset to us. We are all grateful for her contributions to moving Adeza forward." On August 4, 2006, Adeza received a letter from Nasdaq informing the company that, due to Ms. Burrus' resignation, the company was no longer in compliance with the requirements for listing on The Nasdaq Global Market under Marketplace Rule 4350(d)(2), which requires that the company's audit committee have at least three independent directors. The letter also informed the company that under Marketplace Rule 4350(d)(4), the company had until its next annual stockholders' meeting to remedy this non-compliance. Greg Vontz, an independent director of the company, has been appointed to Adeza's audit committee. On August 8, 2006, Nasdaq notified Adeza that the appointment of Mr. Vontz to the audit committee restored the company's compliance with Rule 4350(d)(2) and that the matter is now closed. About Adeza Adeza designs, manufactures and markets innovative products for women's health. Adeza's initial focus is on reproductive healthcare using its proprietary technologies to predict preterm birth and assess infertility. Adeza's principal product is a patented diagnostic test, FullTerm(TM), The Fetal Fibronectin Test, which utilizes a single-use, disposable cassette and is analyzed on Adeza's patented TLiIQ(R) System. This product is approved by the U.S. Food and Drug Administration (FDA) for use in assessing the risk of preterm birth. Adeza also markets and sells the E-tegrity(R) Test, an infertility-related test to assess receptivity of the uterus to embryo implantation in women with unexplained infertility. In May 2006, Adeza announced the submission of its New Drug Application (NDA) to the FDA for Gestiva(TM), a long-acting form of a naturally occurring progesterone to prevent preterm birth in women with a history of preterm delivery. Adeza's NDA submission includes data from a clinical study conducted by the National Institutes of Health. In June 2006, the NDA for Gestiva was granted Priority Review status and given an August 29, 2006 FDA Advisory Committee review date. More information is available at www.adeza.com. Adeza cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements, including for example, statements related to Gestiva's regulatory status and medical potential. The inclusion of forward-looking statements should not be regarded as a representation by Adeza that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Adeza's business including, without limitation, risks related to the anticipated regulatory or commercial path for its product candidates. Further information about these and other risks is included Adeza's Annual Report on Form 10-K and other periodic and current reports filed by Adeza with the Securities Exchange Commission (SEC), which are available from the SEC's Web site (www.sec.gov), and also available on the Investor Relations section of Adeza's Web site. All forward-looking statements are qualified in their entirety by this cautionary statement and Adeza undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.